Clinical Development Network Across Global Newsroom Participants Member Login Submit an RFP

Solutions · Medical Writing | Regulatory and Scientific Documentation | Guosa Life Sciences

Scientific Communication That Advances Clinical Development

Q: Do you write for regulatory submissions and publications?

Yes, from protocols, investigator brochures, and clinical study reports to peer-reviewed manuscripts and conference materials.

Clear. Accurate. Regulatory-Ready.

Scientific communication is essential throughout the development lifecycle. High-quality medical writing transforms complex information into clear, accurate, regulatory-compliant documentation that supports operations, submissions, publication and decision-making.

Submit an RFP

Home/Solutions/Medical Writing | Regulatory and Scientific Documentation | Guosa Life Sciences

Overview

Clear. Accurate. Regulatory-Ready.

Guosa Life Sciences provides comprehensive Medical Writing delivered by experienced scientific professionals with expertise across therapeutic areas, regulatory frameworks and development phases.

Every protocol, investigator brochure, clinical study report and submission contributes to the successful advancement of a development program.

Regulatory and scientific medical writing

Capabilities

What We Deliver

Regulatory Writing

Protocols and amendments
Investigator brochures
Clinical study reports
Regulatory submission documents

Scientific Writing

Manuscripts and publications
Abstracts and posters
Plain-language summaries
Safety narratives

The GLS Advantage

Strengthened by the Whole Enterprise

Every solution delivered by Guosa Life Sciences is strengthened by the broader enterprise. Our operational teams are supported by evidence-based Insights, professional development through GLS Academy, collaborative partnerships within the Clinical Development Network and a quality-driven delivery model, enabling scientifically sound, operationally efficient and scalable solutions.

Explore the Enterprise

Evidence-based Insights
GLS Academy development
Clinical Development Network
Integrated quality systems
Technology-enabled delivery
Global operational reach

The capability

What We Actually Do

We write the documents a program runs on: protocols and amendments, investigator brochures, informed consent forms, clinical study reports, integrated summaries, regulatory responses, and manuscripts and conference materials arising from the work.

Writing quality is largely determined before drafting begins. We work from an agreed document plan with defined source data, a single reviewer chain and version discipline, because most delay in medical writing is caused by unresolved contributor comments rather than by drafting speed.

Regulatory considerations

Submission dossier requirements across regions

Clinical study reports follow ICH E3 structure, but the surrounding submission requirements diverge by region and by product type. Content that is expected as an appendix in one jurisdiction may be required in the body in another; some authorities require a lay summary or a specific patient information format; and several African regulators expect a submission format that does not map cleanly onto either a US or EU dossier.

Informed consent documentation is where the divergence is sharpest and the risk highest. Ethics committees frequently require local language versions, specific compensation and ancillary care language, and provisions on future use of samples that differ from the sponsor's global template. Where research is conducted in low-resource settings, CIOMS guidance on undue inducement and ancillary care obligations shapes what a committee will accept. We draft against the local requirement rather than translating a template and hoping.

How an engagement runs

The Sequence

1. Document plan

Scope, source data, contributor list, review cycles and dates agreed before drafting.

2. Draft

Written against the applicable structure and the specific requirements of the target authorities.

3. Review

Consolidated comment resolution with a single version of truth and documented decisions on contested points.

4. Finalize

Quality control against source, reference verification, and delivery in the required format.

What you receive

Deliverables

An agreed document plan with dates. Drafts written to the applicable regional structure. A documented comment resolution record. Final documents quality-controlled against source data.

Evidence and context

The Research Behind This Work

Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.

The Future of Clinical Trials in Africa The Untapped Advantage

Regulatory Affairs

Submission-ready documents.

Explore

Data and Biostatistics

CSR and analysis.

Explore

Pharmacovigilance

Safety narratives.

Explore

Insights

Scientific publishing.

Explore

FAQ

Common Questions

Do you write for regulatory submissions and publications?

Yes, from protocols, investigator brochures and clinical study reports to peer-reviewed manuscripts and conference materials.

Do your writers have therapeutic-area expertise?

Yes. Our medical writers bring expertise across therapeutic areas, regulatory frameworks and clinical development phases.

Let's Discuss Your Program

Tell us about your objectives and our multidisciplinary team will scope an integrated, flexible solution.

Submit an RFP

Scientific Communication That Advances Clinical Development

Clear. Accurate. Regulatory-Ready.

What We Deliver

Regulatory Writing

Scientific Writing

Strengthened by the Whole Enterprise

What We Actually Do

Submission dossier requirements across regions

The Sequence

1. Document plan

2. Draft

3. Review

4. Finalize

Deliverables

The Research Behind This Work

Explore Related Capabilities

Regulatory Affairs

Data and Biostatistics

Pharmacovigilance

Insights

Common Questions

Let's Discuss Your Program